{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:20:57Z","timestamp":1787235657969,"version":"build-2736575974"},"reference-count":25,"publisher":"Scientific Scholar","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"\n Background & objectives:<\/jats:title>\n Statins are one of the most widely used drugs and have antilipidemic effects as well as antioxidant, anti-inflammatory, anti-angiogenic and anti-tumorigenic effects. It has been shown that the synergistic combinations of statins which can provide better clinical benefit in the treatment of cancer and if administered with other anticancer agents, may be an alternative treatment modality. The aim of this study was to assess the efficacy of administrating statin in multiple myeloma (MM) cell line on cell proliferation.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n U266 myeloma cells were cultured in 25 or 75 cm\n 2<\/jats:sup>\n flasks by using cell culture medium mixtures obtained with the supplementation of 10 per cent foetal bovine serum and one per cent of penicillin-streptomycin into RPMI 1640 medium. When the cells reached confluence (reached to the density of 70%), they were reproduced by passaging. Cytotoxicity was evaluated by using the XTT test.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Statins (atorvastatin and simvastatin), were administered to the U266 myeloma cell line at 100, 50, 25, 12.5, 6.25 and 3.12 \u03bcM concentrations. Inhibitor concentration 50 (IC\n 50<\/jats:sub>\n ) values calculated for atorvastatin and simvastatin were determined as 94 and 38 \u03bcM, respectively. While 100, 50, 25, 12.5, 6.25 and 3.12 \u03bcM concentrations were used for bortezomib, the IC\n 50<\/jats:sub>\n value calculated for this agent was 18.2 nM. When six concentrations of bortezomib used in the study were combined with 12.5 \u03bcM inactive concentrations of statins that did not cause inhibition in cell proliferation, both atorvastatin and simvastatin increased the effect of bortezomib at all the concentrations used, and simvastatin showed a stronger efficacy than atorvastatin.\n <\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions:<\/jats:title>\n \n Our\n in vitro<\/jats:italic>\n results indicated that atorvastatin and simvastatin when used along with the conventional treatment in myeloma patients, may improve the effectiveness of the standard therapy and prevent the bortezomib-induced cytotoxic and neurotoxic side effects when used at a low dose. Further studies need to be done in MM patints to confirm these findings.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_672_18","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T08:32:15Z","timestamp":1580373135000},"page":"630-634","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["In vitro comparison of the cytotoxic effects of statins on U266 myeloma cell line"],"prefix":"10.25259","volume":"150","author":[{"given":"Hatice","family":"Terzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Altun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"\u015eencan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R1-15-20241212","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-15-20241212","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet"},{"key":"R3-15-20241212","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-10-3366","article-title":"Oncogenomics to target myeloma in the bone marrow microenvironment","volume":"17","author":"Anderson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R4-15-20241212","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"R5-15-20241212","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"R6-15-20241212","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"R7-15-20241212","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2013.49.2124","article-title":"Minimal residual disease in multiple myeloma","volume":"31","author":"Munshi","year":"2013","journal-title":"J Clin Oncol"},{"key":"R8-15-20241212","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14728214.2012.713345","article-title":"Emerging biological insights and novel treatment strategies in multiple myeloma","volume":"17","author":"Gentile","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"R9-15-20241212","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1038\/bcj.2015.60","article-title":"Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib","volume":"5","author":"Kumar","year":"2015","journal-title":"Blood Cancer J"},{"key":"R10-15-20241212","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/BLCTT.S91251","article-title":"Managing treatment-related peripheral neuropathy in patients with multiple myeloma","volume":"6","author":"Grammatico","year":"2016","journal-title":"Blood Lymphat Cancer"},{"key":"R11-15-20241212","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"R12-15-20241212","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf","year":"2012","journal-title":"Haematologica"},{"key":"R13-15-20241212","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.3324\/haematol.2013.100396","article-title":"Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma","volume":"99","author":"Lok","year":"2014","journal-title":"Haematologica"},{"key":"R14-15-20241212","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.3324\/haematol.2014.118182","article-title":"Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: Subanalysis of patients with renal impairment in the phase III MMY-3021 study","volume":"100","author":"Moreau","year":"2015","journal-title":"Haematologica"},{"key":"R15-15-20241212","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R16-15-20241212","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.leu.2402476","article-title":"HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis","volume":"16","author":"Wong","year":"2002","journal-title":"Leukemia"},{"key":"R17-15-20241212","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.tiv.2010.06.015","article-title":"The compound cis-(dichloro)tetrammineruthenium(III) chloride induces caspase-mediated apoptosis in K562 cells","volume":"24","author":"de Lima","year":"2010","journal-title":"Toxicol In Vitro"},{"key":"R18-15-20241212","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00280-013-2326-3","article-title":"Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients","volume":"72","author":"Ahmed","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"R19-15-20241212","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"R20-15-20241212","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/(SICI)1097-0215(20000515)86:4<553::AID-IJC18>3.0.CO;2-9","article-title":"Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398","volume":"86","author":"Elder","year":"2000","journal-title":"Int J Cancer"},{"key":"R21-15-20241212","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/j.1440-1746.2006.04366.x","article-title":"Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells","volume":"21","author":"Li","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R22-15-20241212","first-page":"583","article-title":"Effects of selective cyclooxygenase-2 inhibitor NS-398 on 5-fluorouracil chemotherapy and progression of colon cells: An experimental study","volume":"84","author":"Zhang","year":"2004","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R23-15-20241212","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.currproblcancer.2009.01.001","article-title":"Multiple myeloma","volume":"33","author":"Rajkumar","year":"2009","journal-title":"Curr Probl Cancer"},{"key":"R24-15-20241212","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.exphem.2011.11.008","article-title":"Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients","volume":"40","author":"van der Weide","year":"2012","journal-title":"Exp Hematol"},{"key":"R25-15-20241212","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/s10495-014-1002-3","article-title":"Indomethacin promotes apoptosis in gastric cancer cells through concomitant degradation of survivin and aurora B kinase proteins","volume":"19","author":"Chiou","year":"2014","journal-title":"Apoptosis"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmr.IJMR_672_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T19:02:59Z","timestamp":1751482979000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/in-vitro-comparison-of-the-cytotoxic-effects-of-statins-on-u266-myeloma-cell-line\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_672_18","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}